Andy Studna

Hopeful new standard of care for advanced prostate cancer capitalizing on momentum.

Our editorial team presents the winners of our annual Emerging Pharma Leaders and their up-and-coming perspectives on a range of industry topics.

Script change from destined life in research to wild pace of biotech pays off.

A passion for building the business engine behind treatments for rare disease.

Launching a big pharma biotech incubator during the pandemic.

Looking Back at 1990-1993.

Following the announcement of his new role, Pharm Exec had the chance to speak with Daniel Schroen, PhD about his past experience as well as the landscape of the therapeutic development industry.

The role of advanced data technologies in reducing hurdles.

In the second of MJH Life Sciences' State of the Physician reports, over 1,600 respondents weighed in on how they have been affected financially by COVID-19 and what it means for them moving forward.

A new series of surveys has been released by MJH titled State of the Physician. The first focuses on how physicians are communicating with their patients during COVID-19.